|
Having trouble viewing this email? View it as a Web page.
| If you have trouble reading this e-mail, please click here. |
 |
|
Recommendations and Reports
Volume 62, No. RR-9
October 25, 2013 |
|
|
|
|
| Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis |
|
| |
|
The Food and Drug Administration (FDA) has approved use of bedaquiline
fumarate (Sirturo or bedaquiline)
for treatment of multidrug-resistant tuberculosis (MDR TB) in certain persons under
the provisions of the accelerated
approval regulations for “Serious or
Life-Threatening Illnesses.” This report provides provisional CDC guidance for the use and safety monitoring of bedaquiline in persons who receive a diagnosis of MDR TB. These guidelines are intended for health-care professionals who might use bedaquiline
for the treatment of MDR TB. |
|
 full text |
|
|
| |
Department of Health and Human Services
Centers for Disease Control and Prevention |
| This email was sent to list-cdc@xxxxxxxxxxx using GovDelivery, on behalf of: Centers for Disease Control and Prevention (CDC) · 1600 Clifton Rd · Atlanta, GA 30333 · 1-800-CDC-INFO (800-232-4636) |
 |
|
